Biora Therapeutics announced initiation of its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers. BT-600 is a drug-device combination program consisting of the orally administered NaviCap device which delivers a unique, liquid formulation of tofacitinib to the colon for the potential treatment of moderate to severe ulcerative colitis.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIOR:
- Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
- Biora shares ‘reaching a key tipping point,’ says H.C. Wainwright
- Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
- Biora Therapeutics progresses research collaboration for BioJet platform
- Biora Therapeutics files to sell 71.07M shares of common stock for holders